Current challenges and future perspectives in oral absorption research: An opinion of the UNGAP network.

Advanced formulations Amorphous solid dispersions Food-drug interactions In vitro tools Lipid-based formulations Microbiome PBPK modeling Regional differences Specific patient populations

Journal

Advanced drug delivery reviews
ISSN: 1872-8294
Titre abrégé: Adv Drug Deliv Rev
Pays: Netherlands
ID NLM: 8710523

Informations de publication

Date de publication:
04 2021
Historique:
received: 27 11 2020
revised: 12 01 2021
accepted: 01 02 2021
pubmed: 22 2 2021
medline: 24 11 2021
entrez: 21 2 2021
Statut: ppublish

Résumé

Although oral drug delivery is the preferred administration route and has been used for centuries, modern drug discovery and development pipelines challenge conventional formulation approaches and highlight the insufficient mechanistic understanding of processes critical to oral drug absorption. This review presents the opinion of UNGAP scientists on four key themes across the oral absorption landscape: (1) specific patient populations, (2) regional differences in the gastrointestinal tract, (3) advanced formulations and (4) food-drug interactions. The differences of oral absorption in pediatric and geriatric populations, the specific issues in colonic absorption, the formulation approaches for poorly water-soluble (small molecules) and poorly permeable (peptides, RNA etc.) drugs, as well as the vast realm of food effects, are some of the topics discussed in detail. The identified controversies and gaps in the current understanding of gastrointestinal absorption-related processes are used to create a roadmap for the future of oral drug absorption research.

Identifiants

pubmed: 33610694
pii: S0169-409X(21)00035-1
doi: 10.1016/j.addr.2021.02.001
pii:
doi:

Substances chimiques

Pharmaceutical Preparations 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

289-331

Informations de copyright

Copyright © 2021 The Authors. Published by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest None.

Auteurs

Zahari Vinarov (Z)

Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium; Department of Chemical and Pharmaceutical Engineering, Sofia University, Sofia, Bulgaria.

Bertil Abrahamsson (B)

Oral Product Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Gothenburg, Sweden.

Per Artursson (P)

Department of Pharmacy, Uppsala University, Uppsala, Sweden.

Hannah Batchelor (H)

Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, United Kingdom.

Philippe Berben (P)

Pharmaceutical Development, UCB Pharma SA, Braine- l'Alleud, Belgium.

Andreas Bernkop-Schnürch (A)

Department of Pharmaceutical Technology, Institute of Pharmacy, University of Innsbruck, Innsbruck, Austria.

James Butler (J)

GlaxoSmithKline Research and Development, Ware, United Kingdom.

Jens Ceulemans (J)

Janssen Pharmaceutica NV, Beerse, Belgium.

Nigel Davies (N)

Advanced Drug Delivery, Pharmaceutical Sciences, R&D, AstraZeneca, Gothenburg, Sweden.

Didier Dupont (D)

INRAE, Institut Agro, STLO, Rennes, France.

Gøril Eide Flaten (GE)

Department of Pharmacy, UiT The Arctic University of Norway, Tromsø, Norway.

Nikoletta Fotaki (N)

Department of Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom.

Brendan T Griffin (BT)

School of Pharmacy, University College Cork, Cork, Ireland.

Vincent Jannin (V)

Lonza Pharma & Biotech, Colmar, France.

Janneke Keemink (J)

Janssen Pharmaceutica NV, Beerse, Belgium.

Filippos Kesisoglou (F)

Pharmaceutical Sciences, Merck & Co. Inc., Rahway, NJ, USA.

Mirko Koziolek (M)

Abbvie Deutschland GmbH & Co. KG, Ludwigshafen, Germany.

Martin Kuentz (M)

Institute for Pharma Technology, University of Applied Sciences and Arts Northwestern Switzerland, Basel, Switzerland.

Alan Mackie (A)

School of Food Science & Nutrition, University of Leeds, Leeds, United Kingdom.

Antonio J Meléndez-Martínez (AJ)

Food Colour & Quality Laboratory, Area of Nutrition & Food Science, Universidad de Sevilla, Seville, Spain.

Mark McAllister (M)

Drug Product Design, Pfizer PGRD, Sandwich, United Kingdom.

Anette Müllertz (A)

Department of Pharmacy, University of Copenhagen, Copenhagen, Denmark.

Caitriona M O'Driscoll (CM)

School of Pharmacy, University College Cork, Cork, Ireland.

Neil Parrott (N)

F. Hoffmann-La Roche Ltd, Basel, Switzerland.

Jadwiga Paszkowska (J)

Physiolution Polska Sp. Z o.o., Wroclaw, Poland.

Petr Pavek (P)

Faculty of Pharmacy, Charles University, Hradec Králové, Czech Republic.

Christopher J H Porter (CJH)

Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Australia.

Christos Reppas (C)

Department of Pharmacy, National and Kapodistrian University of Athens, Athens, Greece.

Cordula Stillhart (C)

F. Hoffmann-La Roche Ltd, Basel, Switzerland.

Kiyohiko Sugano (K)

College of Pharmaceutical Sciences, Ritsumeikan University, Shiga, Japan.

Elena Toader (E)

Faculty of Medicine, University of Medicine and Pharmacy of Iasi, Romania.

Kateřina Valentová (K)

Institute of Microbiology of the Czech Academy of Sciences, Prague, Czech Republic.

Maria Vertzoni (M)

Department of Pharmacy, National and Kapodistrian University of Athens, Athens, Greece.

Saskia N De Wildt (SN)

Department of Pharmacology and Toxicology, Radboud University Medical Center, Nijmegen, the Netherlands.

Clive G Wilson (CG)

Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, United Kingdom.

Patrick Augustijns (P)

Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium. Electronic address: patrick.augustijns@kuleuven.be.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH